Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 16/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 15/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905848 | 0.86 | MKNK1 (0.66) | MKNK1MKNK2HIF1AKCNH3CCNT1 | |
| SCHEMBL4906924 | 0.86 | MKNK1 (0.59) | MKNK1MKNK2KDM4EGAAHTT | |
| SCHEMBL18803536 | 0.84 | MKNK1 (1.00) | MKNK1MKNK2CCNT1CCNA2CDK2 | |
| SCHEMBL3645075 | 0.84 | MKNK1 (0.60) | MKNK1MKNK2HIF1AKCNH3CCNT1 | |
| SCHEMBL7471338 | 0.83 | MKNK1 (0.51) | MKNK1MKNK2 | |
| SCHEMBL7451097 | 0.80 | PRKCA (0.51) | MKNK1MKNK2KDM4EHTTCCNT1 | |
| SCHEMBL4907136 | 0.79 | MKNK1 (0.55) | MKNK1MKNK2KCNH3CCNT1CCNA2 | |
| SCHEMBL28133994 | 0.78 | HPGD (0.59) | MKNK1MKNK2KCNH3 | |
| SCHEMBL18803533 | 0.77 | MKNK1 (1.00) | MKNK1MKNK2CCNT1CCNA2CDK2 | |
| SCHEMBL16450076 | 0.75 | HTR7 (0.51) | MKNK1MKNK2KCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | MKNK1 682/4885MKNK2 701/4885HIF1A 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.